CONTRAFECT Corp
CONTRAFECT Corp (CFRX): 1 pipeline candidate · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
2.0 months
D/E -2.58 · 0% dilution
N/A
1 candidate
N/A
N/A
A transparent, data-derived signal for CONTRAFECT Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$5.4M
Quarterly Burn
$8.7M
Runway
2.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| exebacase | — |
Frequently asked questions
How many drug candidates are in CONTRAFECT Corp's pipeline?
CONTRAFECT Corp (CFRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is CONTRAFECT Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CONTRAFECT Corp has approximately 2.0 months of cash runway.
Who is the CEO of CONTRAFECT Corp?
Roger J. Pomerantz, M.D. is the chief executive officer of CONTRAFECT Corp (CFRX).
Get the full picture on CONTRAFECT Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.